Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP-001 plus corticosteroids for high-risk acute graft-versus-host disease
2022-502673-41-01Phase 2Completed
- Sponsor
- Cynata Therapeutics
- Start
- Mar 2024
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing CYP-001 plus corticosteroids with Placebo plus corticosteroids (2 arms). Primary endpoint: Overall response rate at Day 28. Started Mar 2024; status: completed.
02
Drugs
Cymerus MSCs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2022-502673-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502673-41-01.